Ardelyx Inc.’s tenapanor is on track for an FDA approval decision in irritable bowel syndrome with constipation (IBS-C) by mid-September 2019, but the company is still seeking a US partner.
“Tenapanor would be the first medication available that works by reducing sodium uptake from the gut,” Ardelyx emphasized in its...







